Boy dies during Pfizerâs clinical trial probing rare genetic disease
HQ Team May 8, 2024: A young boy, treated for a rare genetic disease, died during a mid-stage clinical trial conducted by Pfizer,.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team May 8, 2024: A young boy, treated for a rare genetic disease, died during a mid-stage clinical trial conducted by Pfizer,.
HQ Team April 30, 2024: The US health regulator has approved Pfizerâs drug to treat cervical cancer patients whose disease has progressed beyond.
HQ Team April 25, 2024: The US health regulator has approved a drug of Utility Therapeutics to treat adult women, 18 years or.
HQ Team April 9, 2024: Pfizer Inc., announced its experimental drug for treating a lower respiratory tract disease for adults between 18- to.
HQ Team April 4, 2024: Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the.
HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica Internationalâs Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.
HQ Team April 1, 2024: Preventing the spread of sexually transmitted infections (STIs) might soon be as simple as taking a couple of.
HQ Team March 29, 2024: Bristol Myers Squibbâs final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohnâs.
US-based biotechnology company Viking Therapeutics Inc., reported âpositiveâ results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.
HQ Team March 25, 2024: Novo Nordisk, one of the worldâs most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.